Hungary - GSK
WEBHungary. At GSK, we unite science, technology and talent to get ahead of disease together. We prevent and treat disease with vaccines, specialty and general medicines investing in four core therapeutic areas: infectious …
GSK consolidates DT and TT vaccine production in Hungary plant, adding ...
WEBMar 13, 2017 · With GlaxoSmithKline’s vaccines sales expanding, it figures it needs expanded production as well and some of that will happen at a 10-year-old plant in Hungary as well as Germany.
GlaxoSmithKline – Wikipédia
WEBA GlaxoSmithKline (röviden: GSK) az egyik legnagyobb multinacionális gyógyszeripari vállalat, melynek központja az Egyesült Királyság. Kutatásorientált gyógyszeripari vállalat, fő terápiás területei: asztma és COPD; trombózis; fertőzések; központi idegrendszer betegségei; daganatos betegségek; betegségek megelőzése ...
Átszervezi működését Magyarországon a GSK, a gyára és
WEBOct 20, 2020 · A GSK globális központja úgy döntött, hogy 16 európai országban, köztük Magyarországon is, a jövőben egy új működési modellben fogja terápiáit és védőoltásait elérhetővé tenni a magyar betegek és orvosok számára.
“Magyar Manufaktúra”: Hungary’s Pharma Manufacturing Resurgence
WEBFeb 6, 2016 · While GSK’s dynamic history in Hungary has long been apparent, this latest on-the-ground investment signifies a willingness to bet big on a country that is looking increasingly competitive as a pharmaceuticals manufacturing destination.
GlaxoSmithKline expanding vaccine production in Hungary
WEBMar 16, 2017 · British drugmaker GlaxoSmithKline has invested HUF 18 billion ($62.5 million) into its Hungarian vaccine unit, consolidating diphtheria toxoid and tetanus toxoid manufacturing for the vaccines Infanrix and Synflorix …
GlaxoSmithKline to upgrade Gödöllő plant creating new jobs
WEBMar 14, 2017 · Leading pharmaceutical firm GlaxoSmithKline (GSK) has announced that it will upgrade its plant in Gödöllő near Budapest, creating 104 new jobs. According to sources, the British company will increase production on vaccines to cater for the growing demand worldwide.
Interview: Claire Roger – General Manager, GSK Hungary
WEBGSK Hungary's Claire Roger discusses the value of ethical promotion both in improving transparency and benefiting all stakeholders. She further describes the strategic role and economic impact of GSK’s vaccine plant in Gödöllő and growth opportunities in HIV.
Government - Ministry of Foreign Affairs and Trade - News
WEB“In future, GSK will be able to produce all of its Diphtheria Toxoid and Tetanus Toxoid products in one place, in Gödöllő, which will result in the simplification and increased efficiency of vaccine production processes”, the Managing Director added.
Vaccine manufacturing in Gödöllő has gained strategic importance ...
WEBBy employing some 300 people based on the latest figures, the site of the manufacturing unit in Gödöllő manufactures two types of antigens (diphtheria and tetanus). Over the last decades, the Hungarian site has proven to represent world-class, high added value within the GSK network.
Skip to content